Lachlan Brown
Stock Analyst at William Blair
(2.00)
# 2,991
Out of 4,944 analysts
10
Total ratings
50%
Success rate
4.94%
Average return
Main Sectors:
Stocks Rated by Lachlan Brown
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| MANH Manhattan Associates | Downgrades: Neutral | $270 → $200 | $212.75 | -5.99% | 2 | Jun 10, 2025 | |
| HROW Harrow | Initiates: Outperform | n/a | $34.83 | - | 1 | Jun 10, 2025 | |
| KLRS Kalaris Therapeutics | Initiates: Outperform | n/a | $2.49 | - | 1 | Apr 8, 2025 | |
| OCUL Ocular Therapeutix | Initiates: Outperform | n/a | $12.48 | - | 1 | Apr 8, 2025 | |
| SNPS Synopsys | Initiates: Buy | $600 | $625.80 | -4.12% | 1 | Jan 13, 2025 | |
| CDNS Cadence Design Systems | Initiates: Buy | $350 | $353.61 | -1.02% | 1 | Jan 13, 2025 | |
| APLS Apellis Pharmaceuticals | Initiates: Outperform | n/a | $23.90 | - | 1 | Oct 16, 2024 | |
| DSGX The Descartes Systems Group | Initiates: Neutral | $90 | $99.36 | -9.42% | 1 | May 14, 2024 | |
| SPSC SPS Commerce | Initiates: Buy | $220 | $108.50 | +102.77% | 1 | May 14, 2024 |
Manhattan Associates
Jun 10, 2025
Downgrades: Neutral
Price Target: $270 → $200
Current: $212.75
Upside: -5.99%
Harrow
Jun 10, 2025
Initiates: Outperform
Price Target: n/a
Current: $34.83
Upside: -
Kalaris Therapeutics
Apr 8, 2025
Initiates: Outperform
Price Target: n/a
Current: $2.49
Upside: -
Ocular Therapeutix
Apr 8, 2025
Initiates: Outperform
Price Target: n/a
Current: $12.48
Upside: -
Synopsys
Jan 13, 2025
Initiates: Buy
Price Target: $600
Current: $625.80
Upside: -4.12%
Cadence Design Systems
Jan 13, 2025
Initiates: Buy
Price Target: $350
Current: $353.61
Upside: -1.02%
Apellis Pharmaceuticals
Oct 16, 2024
Initiates: Outperform
Price Target: n/a
Current: $23.90
Upside: -
The Descartes Systems Group
May 14, 2024
Initiates: Neutral
Price Target: $90
Current: $99.36
Upside: -9.42%
SPS Commerce
May 14, 2024
Initiates: Buy
Price Target: $220
Current: $108.50
Upside: +102.77%